ClinicalTrials.gg
Active, not recruitingNCT07350486LLM-CoManageUpdated Sep 4, 2026

LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia

An interventional study of LLM-Enabled Co-management in Hypertension, Diabetes and Dyslipidemia, sponsored by First Hospital of China Medical University. Active, not recruiting at 6 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by First Hospital of China Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,800
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
19th of 308
6,800 · median 253
Started
2026
with 37 others
No phase
146 of 410
56 open now
Primary completion
2027-03
later than 92 of 147 live
Registered
363rd of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 19th largest by planned enrollment of the 308 interventional ones that give a count, is one of 38 that started in 2026, is one of 146 with no phase, reaches primary completion later than 92 of the 147 other live ones, and was the 363rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of a large language model (LLM)-supported, community-based integrated management model in improving cardiometabolic multimorbidity control among adults with hypertension and coexisting diabetes or dyslipidemia. Adopting an interventional study design, eligible patients will be recruited to compare the disease control indicators between LLM-assisted management and conventional management, so as to verify the effectiveness and safety of the former.

03

Conditions studied

  • Hypertension
  • Diabetes
  • Dyslipidemia

Keywords

  • Large Language Model
  • Co-Management
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Participating communities must meet all of the following criteria:

  • Have a designated community physician responsible for primary care who is capable of using a smartphone with stable internet access for clinical communication and LLM-assisted management;
  • No plan for administrative merger or restructuring within the next three years;
  • Located at least 2 kilometers away from adjacent participating communities (to minimize contamination between clusters).

Eligible participants must fulfill all of the following conditions:

  • Aged 40 years or older;
  • Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg;
  • Coexisting diabetes ( ≥ 7.0%) or coexisting dyslipidemia (LDL-C ≥ 3.4 mmol/L[130 mg/dL]);
  • Able to use a smartphone independently or with assistance from family members;
  • Has resided in the participating community for at least 6 months;
  • Has no plan to relocate in the next 3 years;
  • Enrolled in basic medical insurance for urban and rural residents, employee medical insurance, or the New Rural Cooperative Medical Scheme;
  • Not currently pregnant or planning pregnancy during the study period;
  • Free from malignant tumors and deemed to have a of at least 3 years, as judged by study physicians;
  • Willing and able to provide written .

Exclusion Criteria:No specific exclusion criteria.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,800 participants (estimated)

Study arms

  • Experimental
    LLM-Enabled Intervention Group

    LLM-enabled community physicians delivered integrated, guideline-based management

    Other: LLM-Enabled Co-management

  • No intervention
    Usual Care Control Group

    Community physicians provided routine care according to local primary health service standards

Interventions

  • OtherLLM-Enabled Co-management

    The intervention is a LLM-enabled, community-based integrated management strategy for cardiometabolic multimorbidity. The LLM system functions as the central intelligence layer, integrating multi-condition clinical information, delivering real-time decision support, coordinating care workflows, and facilitating continuous patient engagement. Within this LLM-enabled framework, community physicians-after standardized training-serve as the core executors of care, delivering guideline-based pharmacologic treatment, lifestyle counseling, and structured monitoring of coexisting cardiometabolic conditions. Policy-aligned performance incentives are used to support physician engagement and implementation fidelity, without altering medication access or underlying clinical protocols. The LLM-enabled intervention is implemented through the HyperMind system, an integrated platform that simultaneously supports clinicians, patients, and health-system oversight.

06

What researchers measure

Primary outcomes

  1. The between-group difference in the proportion of participants achieving simultaneous control of hypertension and either diabetes or dyslipidemia.

    Simultaneous control is defined as BP \< 130/80 mmHg and at least one of the following: HbA1c \< 7.0% or LDL-C \< 2.6 mmol/L (100 mg/dL), with a stricter threshold of \< 1.8 mmol/L (70 mg/dL) for participants with cardiovascular disease(CVD).

    Time frame: 6 months after baseline

Secondary outcomes

  1. Net changes in estimated 10-year risk for atherosclerotic CVD.

    Net change in estimated 10-year atherosclerotic cardiovascular disease risk.

    Time frame: 6 months after baseline

  2. Proportion of participants achieving control of individual risk factors: BP < 130/80 mmHg (or < 140/90 mmHg); HbA1c < 7.0%; and LDL-C < 2.6 mmol/L (100 mg/dL) or < 1.8 mmol/L (70 mg/dL) for those with CVD.

    The proportion of participants achieving target control of each individual risk factor, including blood pressure, HbA1c, and LDL-C.

    Time frame: 6 months after baseline

  3. Mean systolic blood pressure changes.

    Mean systolic blood pressure changes of participants.

    Time frame: 6 months after baseline

  4. Mean diastolic blood pressure changes.

    Mean diastolic blood pressure changes of participants.

    Time frame: 6 months after baseline.

  5. Mean HbA1c changes.

    Mean HbA1c changes of participants.

    Time frame: 6 months after baseline.

  6. Mean LDL-C changes.

    Mean LDL-C changes of participants.

    Time frame: 6 months after baseline.

  7. Proportion of participants achieving simultaneous control of BP, HbA1c, and LDL-C.

    The proportion of participants achieving simultaneous control of blood pressure, HbA1c, and LDL-C.

    Time frame: 6 months after baseline

  8. Awareness and treatment rates for hypertension, diabetes, and dyslipidemia.

    Rates of disease awareness and treatment for hypertension, diabetes, and dyslipidemia.

    Time frame: 6 months after baseline

  9. Proportion of participants receiving integrated, guideline-based management of all indicated conditions.

    The proportion of participants receiving integrated, guideline-based management for indicated conditions.

    Time frame: 6 months after baseline

  10. Mean health expenditures and within-trial cost-utility.

    Mean health care expenditures and within-trial cost-utility outcomes.

    Time frame: 6 months after baseline

  11. Changes in treatment adherence.

    Change in treatment adherence among participants.

    Time frame: 6 months after baseline

  12. Improvements in behavioral risk factors (e.g., diet, physical activity, tobacco use, lifestyle intervention uptake).

    Changes in behavioral risk factors including diet, physical activity, and tobacco use.

    Time frame: 6 months after baseline

  13. Patient-reported outcomes related to satisfaction.

    Patient-reported satisfaction with LLM will be assessed using a structured scale.

    Time frame: 6 months after baseline

  14. Patient-reported outcomes related to self-management.

    Patient-reported self-management will be assessed using a structured scale.

    Time frame: 6 months after baseline.

  15. Patient-reported outcomes related to quality of life.

    Patient-reported quality of life will be assessed using a structured scale.

    Time frame: 6 months after baseline.

  16. Adoption and utilization of the LLM system by physicians and patients.

    The extent of physician and patient adoption and use of the LLM-based system.

    Time frame: 6 months after baseline

  17. Patterns of AI-assisted recommendations and digital interactions.

    The patterns of Artificial Intelligence(AI)-assisted recommendations and related digital interactions generated during the study.

    Time frame: 6 months after baseline

07

Study locations

6 sites
  • Cangzhou
    Cangzhou, Hebei, China
  • Wujiang District
    Suzhou, Jiangsu, China
  • Dawa District
    Panjin, Liaoning, China
  • Shenyang
    Shenyang, Liaoning, China
  • Yiwu
    Jinzhou, Zhejiang, China
  • Binhai New Area
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 20, 2026
StartActual
May 14, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07350486
Lead sponsor
First Hospital of China Medical University
Collaborators
Beijing Chao Yang Hospital, Zhejiang University, Shandong Provincial Hospital, Cangzhou Central Hospital
Responsible party
Yingxian Sun (Chief of Department of Cardiology in First Hospital of China Medical University, First Hospital of China Medical University) — Principal investigator
First posted
Jan 20, 2026
Start date
May 14, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Yingxian Sun, MD, PhD
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion